Table 4 Average monthly component costs of each regimen group up to the twelfth month (JPY)
Oxaliplatin-based regimens | Irinotecan-based regimens | Regimens including molecular targeted agents | |
|---|---|---|---|
(n = 13) | (n = 31) | (n = 11) | |
mean (range) | mean (range) | mean (range) | |
Total | 418,463 (280,977–635,115) | 215,499 (141,867–567,549) | 705,460 (411,384–1,056,666) |
Outpatient visits | 6,051 (500–11,000) | 6,329 (3,540–11,000) | 5,375 (0–10,488) |
Hospitalization | 89,935 (14,022–209,077) | 53,584 (0–375,985) | 77,752 (0–192,950) |
Operations and Procedures | 37,353 (0–178,780) | 455 (0–9,860) | 38,222 (0–178,273) |
Tests | |||
Laboratory tests | 15,289 (4,991–38,970) | 11,757 (5,548–41,200) | 12,448 (5,833–24,173) |
Diagnostic imaging tests | 8,512 (0–29,140) | 24,039 (1,493–56,330) | 8,958 (0–23,118) |
Drugs and Administration | |||
Anticancer drugs | 228,539 (136,433–364,332) | 96,853 (58,335–138,086) | 535,214 (177,458–988,262) |
Antiemetics | 8,688 (6,051–19,636) | 9,232 (5,857–12,557) | 6,746 (365–11,972) |
Other drugs | 3,707 (0–19,128) | 708 (0–4,347) | 4,546 (0–32,316) |
Administration | 19,882 (2,200–44,160) | 12,543 (950–42,930) | 16,133 (950–43,610) |
Others | 508 (0–6,600) | 0 | 67(0–733) |
Proportion of hospitalization | 21 % | 25 % | 11 % |
Proportion of anticancer drugs | 58 % | 50 % | 77 % |
Meal fees | 8,677 | 4,001 | 4,639 |
Extra bed fees | 67,290 | 13,364 | 10,350 |